Cardio/Renal Drugs Panel Charter Extended

Federal Register notice: FDA has announced the renewal of its Cardiovascular and Renal Drugs Advisory Committee for an additional two years beyond the charter expiration date. The new charter will be in effect until 8/27/2022. To view the notice, click here.

Read more